Department of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, USA.
MD Anderson Cancer Center, Houston, USA.
J Breast Cancer. 2014 Sep;17(3):287-90. doi: 10.4048/jbc.2014.17.3.287. Epub 2014 Sep 30.
Metaplastic breast cancer (MpBC) is an extremely rare breast cancer subtype, characterized by a heterogeneous phenotype. MpBC aggressive biology is attributed to its stem cell-like characteristics. Since these tumors are largely chemoresistant, novel targeted therapies should be explored. Herein, we report the clinical course of a 59-year-old African American woman with MpBC with a PIK3CA mutation in codon 545, exon 10 (GAG to AAG; p.Glu545Lys) and a TP53 mutation in codon 286, exon 8 (GAA to AAA; p.Glu286Lys). The same mutations were observed in the primary and secondary sites. The patient was treated with a molecularly matched therapy using a combined antiangiogenic and mammalian target of rapamycin kinase inhibitor strategy that included liposomal doxorubicin, bevacizumab, and temsirolimus. Partial remission was achieved. In this report, the scientific rationale underlying the activity of this combination was explored. In conclusion, patients may benefit from being offered molecular profiling early during the course of the disease to receive a therapy guided accordingly.
化生性乳腺癌（MpBC）是一种极为罕见的乳腺癌亚型，其特征为异质性表型。MpBC 具有侵袭性的生物学特性归因于其干细胞样特征。由于这些肿瘤对化疗的耐药性较大，因此应探索新的靶向治疗方法。在此，我们报告一例 59 岁非洲裔美国女性的临床病程，其患有化生性乳腺癌，携带 PIK3CA exon10 密码子 545（GAG 至 AAG；p.Glu545Lys）突变和 TP53 exon8 密码子 286（GAA 至 AAA；p.Glu286Lys）突变。原发和继发部位均观察到相同的突变。该患者接受了一种分子匹配治疗，联合使用抗血管生成和哺乳动物雷帕霉素靶蛋白激酶抑制剂策略，包括脂质体多柔比星、贝伐珠单抗和替西罗莫司。达到部分缓解。在本报告中，探讨了这种联合治疗活性的科学依据。总之，患者可能受益于在疾病过程早期提供分子分析，以便相应地接受治疗。
